126 related articles for article (PubMed ID: 26209605)
1. Effects of cilengitide in osteoclast maturation and behavior.
Chillà A; Bianconi D; Geetha N; Dorda A; Poettler M; Unseld M; Sykoutri D; Redlich K; Zielinski CC; Prager GW
Exp Cell Res; 2015 Sep; 337(1):68-75. PubMed ID: 26209605
[TBL] [Abstract][Full Text] [Related]
2. Cilengitide inhibits metastatic bone colonization in a nude rat model.
Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
[TBL] [Abstract][Full Text] [Related]
3. Cilengitide inhibits osteoclast adhesion through blocking the α
Guo DY; Chen ZH; Fu YF; Li YY; Chen MN; Wu JJ; Yuan ZD; Ye JX; Li X; Yuan FL
Heliyon; 2023 Jul; 9(7):e17841. PubMed ID: 37539209
[TBL] [Abstract][Full Text] [Related]
4. In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.
Lautenschlaeger T; Perry J; Peereboom D; Li B; Ibrahim A; Huebner A; Meng W; White J; Chakravarti A
Radiat Oncol; 2013 Oct; 8():246. PubMed ID: 24153102
[TBL] [Abstract][Full Text] [Related]
5. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
[TBL] [Abstract][Full Text] [Related]
6. Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.
Bretschi M; Cheng C; Witt H; Dimitrakopoulou-Strauss A; Strauss LG; Semmler W; Bäuerle T
J Cancer Res Clin Oncol; 2013 Apr; 139(4):573-83. PubMed ID: 23229276
[TBL] [Abstract][Full Text] [Related]
7. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Tentori L; Dorio AS; Muzi A; Lacal PM; Ruffini F; Navarra P; Graziani G
Oncol Rep; 2008 Apr; 19(4):1039-43. PubMed ID: 18357394
[TBL] [Abstract][Full Text] [Related]
8. Differential Effects of Integrin
Stojanović N; Dekanić A; Paradžik M; Majhen D; Ferenčak K; Ruščić J; Bardak I; Supina C; Tomicic MT; Christmann M; Osmak M; Ambriović-Ristov A
Mol Pharmacol; 2018 Dec; 94(6):1334-1351. PubMed ID: 30262596
[TBL] [Abstract][Full Text] [Related]
9. Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.
Tucci M; Stucci S; Felici C; Cafforio P; Resta L; Rossi R; Silvestris F
Br J Haematol; 2016 Apr; 173(1):59-69. PubMed ID: 26728969
[TBL] [Abstract][Full Text] [Related]
10. Evidence that activation of ASIC1a by acidosis increases osteoclast migration and adhesion by modulating integrin/Pyk2/Src signaling pathway.
Li X; Ye JX; Xu MH; Zhao MD; Yuan FL
Osteoporos Int; 2017 Jul; 28(7):2221-2231. PubMed ID: 28462470
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
[TBL] [Abstract][Full Text] [Related]
12. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
[TBL] [Abstract][Full Text] [Related]
13. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
14. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
[TBL] [Abstract][Full Text] [Related]
15. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
[TBL] [Abstract][Full Text] [Related]
16. Oligodeoxynucleotide targeted to the alphav gene inhibits alphav integrin synthesis, impairs osteoclast function, and activates intracellular signals to apoptosis.
Villanova I; Townsend PA; Uhlmann E; Knolle J; Peyman A; Amling M; Baron R; Horton MA; Teti A
J Bone Miner Res; 1999 Nov; 14(11):1867-79. PubMed ID: 10571687
[TBL] [Abstract][Full Text] [Related]
17. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro.
Gramoun A; Shorey S; Bashutski JD; Dixon SJ; Sims SM; Heersche JN; Manolson MF
J Cell Biochem; 2007 Oct; 102(2):341-52. PubMed ID: 17390341
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
19. The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow.
Meyer dos Santos S; Kuczka K; Picard-Willems B; Nelson K; Klinkhardt U; Harder S
Platelets; 2015; 26(1):59-66. PubMed ID: 24433287
[TBL] [Abstract][Full Text] [Related]
20. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.
Carron CP; Meyer DM; Engleman VW; Rico JG; Ruminski PG; Ornberg RL; Westlin WF; Nickols GA
J Endocrinol; 2000 Jun; 165(3):587-98. PubMed ID: 10828842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
